Acute radiation syndrome

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

Retrieved on: 
월요일, 5월 6, 2024
Acute radiation syndrome, Army, Gilead Sciences, Safety, Survival, RNA, Patent, CNIPA, COVID-19, Vaccine

--

Key Points: 
  • It has a demonstrated safety and efficacy profile, and is well-suited to counter nuclear / chemical exposure and viral pandemic scenarios, being viral mutation-resistant, and easy to administer and distribute
    TEL-AVIV, Israel and RALEIGH, N.C., May 6, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.
  • : 202110229970.9 issued April 29, 2024).
  • "This new patent adds to the existing intellectual property portfolio protecting opaganib across multiple indications and represents the first China patent in the Ebola patent family," said Guy Goldberg, RedHill's Chief Business Officer.
  • "U.S. Army studies suggest that opaganib may be the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering a statistically significant increase in survival.

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Retrieved on: 
수요일, 4월 24, 2024
Acute radiation syndrome, Bangladesh Technical Education Board, PROTECT, Safety, SARS-CoV-2, Austerity, IPS, Military medicine, Consortium, United States Army, Patient, HJF, Hospital, COVID-19, Pharmaceutical industry

RALEIGH, N.C. and TEL-AVIV, Israel, April 24, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of Defense, the PROTECT study is expected to be conducted in the U.S., Thailand, Ivory Coast, South Africa and Uganda, and is estimated to be completed by the end of 2024.

Key Points: 
  • RHB-107 (upamostat) is the first drug being tested in this platform study.
  • Phase 2 study," said Gilead Raday, RedHill's Chief Operating Officer and Head of R&D.
  • "RHB-107 is a novel, potentially broad-acting, host-directed antiviral that is expected to act independently of viral spike protein mutations.
  • RHB-107 is the initial drug being evaluated in the early treatment arm of the study.

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
목요일, 3월 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

Retrieved on: 
화요일, 4월 2, 2024
Mallinckrodt, Inflammation, Pharmacology, McGill University, Organization, Acute radiation syndrome, ARS, KOSDAQ, Research, EDT, Senior, Doctor of Philosophy, IL-7, Human Genome Sciences, Drug development, Division, NIT, Vertex Pharmaceuticals

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).

Key Points: 
  • ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).
  • Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc.
  • In his new role, Dr. Oh will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea.
  • Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech."

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Retrieved on: 
화요일, 3월 5, 2024
Infection, MCM, NIAID, NIH, ARS, TEL, FDA, SPHK2, Food, Acute radiation syndrome, RNCP, Bronchiolitis obliterans, Radiation, Mustard gas, HHS, Administration, COVID-19, Chem, ASPR, CCRP, Fibrosis, Acute respiratory distress syndrome, Development, White lung, Opaganib, Pharmaceutical industry

The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.

Key Points: 
  • The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.
  • "With the alarming increase in global geo-political instability, the opportunity to evaluate opaganib as a potential vital protective agent against chemical attack is inspiring.
  • "Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure.
  • Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute for use against potential chemical weapon attack, if approved by the FDA.

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Retrieved on: 
화요일, 2월 20, 2024
Bangladesh Technical Education Board, Research, Fibrosis, Molecule, ARS, NIH, Inflammation, IL-6, FDA, TEL, Food, Acute radiation syndrome, RNCP, Radiation, Mustard gas, COVID-19, Canadian International Council, Survival, Opaganib, Medical imaging

The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy.

Key Points: 
  • The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy.
  • Radiation-induced inflammation is known to occur in two phases – in an initial inflammatory response immediately after irradiation and in a delayed response that can occur weeks later.
  • Thus, treating with opaganib during both initial and delayed phases of inflammation provided the greatest improvement in survival.
  • "These data further demonstrate that sphingolipid metabolism is a critical regulator of fibrogenesis, and specifically show that opaganib suppresses radiation-induced pulmonary inflammation and fibrosis."

NeoImmuneTech Welcomes a New President for its Development and Business

Retrieved on: 
월요일, 1월 15, 2024
Senior, Research, Human Genome Sciences, Biosimilar, NIT, Pharmacology, McGill University, Division, Drug development, Inflammation, Acute radiation syndrome, Organization, Doctor of Philosophy, IL-7, ARS, Mallinckrodt, Vertex Pharmaceuticals, Pharmaceutical industry

ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

Key Points: 
  • ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.
  • Dr. Oh is an expert in regulatory policies and drug development, encompassing both biologics and small molecules.
  • Se Hwan Yang, Ph.D., Chief Executive Officer of NeoImmuneTech, Inc. said: "We are delighted to welcome Dr. Oh to our team.
  • His strong expertise and extensive network are invaluable assets that will propel our clinical development program and business activities.

FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome

Retrieved on: 
월요일, 11월 20, 2023
Medicine, NIAID, Research, Safety, Immune system, Food, ARS, NIT, Hope, ODD, Radiation exposure, FDA, Acute radiation syndrome, NIH, Orphan drug, Bangladesh Technical Education Board, Bone marrow, Infection, Pharmaceutical industry

The FDA's Orphan Drug Designation is aimed at advancing treatments for rare diseases, including Acute Radiation Syndrome (ARS), which currently has limited treatment options.

Key Points: 
  • The FDA's Orphan Drug Designation is aimed at advancing treatments for rare diseases, including Acute Radiation Syndrome (ARS), which currently has limited treatment options.
  • NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS.
  • ROCKVILLE, Md, Nov. 20, 2023 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their investigational drug NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of Acute Radiation Syndrome (ARS).
  • ARS is an illness that occurs following a high dose of radiation exposure, leading to severe damage to the bone marrow and the immune system.

Senator Mark Warner Visits ReAlta Life Sciences’ Biotech Research Facility, Highlights Importance of Rare Disease Innovation

Retrieved on: 
목요일, 10월 12, 2023
Biotechnology, White House, Federal Government, Health, Healthcare Reform, Pharmaceutical, Other Policy Issues, Other Science, Research, Public Policy, Government, Science, Clinical Trials, Multimedia, Chief Management Officer of the Department of Defense, Doctor of Philosophy, CSO, Asphyxia, COVID, Sepsis, MD, Graft-versus-host disease, Warner, United States Senate Select Committee on Nutrition and Human Needs, HIE, CMO, Hypoxia (medical), Rodels-Realta railway station, Immune system, Military personnel, Senator Warner, Acute radiation syndrome, BARDA, Patient, United States Senate Select Committee on Intelligence, Pharmaceutical industry, Intelligence

ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231012073021/en/
    Sen. Mark Warner (D-Va) with ReAlta CEO Dr. Ulrich Thienel, board chairman Edward Heidt, Jr., CMO Dr. Kenji Cunnion, CSO Dr. Neel Krishna, and ReAlta staff.
  • “ReAlta is on the cutting edge of research in a variety of fronts – from COVID to birth asphyxia,” said Sen. Mark R. Warner.
  • The company looks forward to continuing to push the boundaries of what is possible in the fight against life-threatening rare diseases.

Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury

Retrieved on: 
수요일, 9월 6, 2023
Defense, Other Science, Radiology, White House, Federal Government, Pharmaceutical, Research, Other Defense, Oncology, Contracts, Homeland Security, Science, Clinical Trials, Public Policy, Government, FDA, Biotechnology, Health, Law Enforcement, Emergency Services, COVID-19, Military, BIO, Radiation, Acute radiation syndrome, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, ARS, United States Department of Defense, OTA, Policy, Clinical trial, Cancer, Lung cancer, Food and Drug Administration, Terrorism, Bangladesh Technical Education Board, DOD, JPM, Humanetics, Patient, Joint Program Executive Office Chemical and Biological Defense, Chronic radiation syndrome, Conventional weapon, Radiation exposure, Food, Pharmaceutical industry, Vaccine, Chemical substance

Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.

Key Points: 
  • Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.
  • In addition, the OTA agreement provides options for the DOD to fund all activities required to bring BIO 300 to full FDA approval.
  • Exposure to radiation from accidental or intentional sources can lead to acute radiation syndrome (ARS), which consists of numerous serious and life-threatening injuries.
  • The JPEO-CBRND will manage the OTA agreement, overseeing the development of BIO 300, exclusively licensed to Humanetics for advanced development and FDA licensing.